Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

NCT04337359 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Severe/Very Severe COVID-19 Illness

Interventions

DRUG: Ruxolitinib

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]